| Page 5 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria

Author(s): 
Koschmieder S, Panse J
Primary Author: 
Koschmieder S
Journal Title: 
Hamostaseologie
Original Publication Date: 
Apr 2025

Patients with thrombosis at an unusual site will need to be explored for rare causes of thrombosis. Two of these rare causes include myeloproliferative neoplasms (MPNs) and

Bone Marrow Disease(s): 

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies

Author(s): 
Risitano AM, de Castro C, Han B, Kulasekararaj A, Maciejewski JP, Scheinberg P, Ueda Y, Vallow S, Bermann G, Dahlke M, Kumar R, Peffault de Latour R
Primary Author: 
Risitano AM
Journal Title: 
Blood Advances
Original Publication Date: 
Apr 2025

Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH; NCT04558918) and C5i-naive (APPOINT-PNH; NCT04820530) patients with

Bone Marrow Disease(s): 

Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry

Author(s): 
Houtman B, Taylor A, Van Marrewijk C, Smith A, Fenaux P, Cargo C, Symeonidis A, Mittelman M, Stauder R, Čermák J, Sanz G, Hellström-Lindberg E, Malcovati L, Adès L, Comont T, Culligan D, Kotsianidis I, De Witte T, Blijlevens N, Langemeijer S, Hoeks M;
Primary Author: 
Houtman B
Journal Title: 
Haematologica
Original Publication Date: 
Apr 2025

Infections are an important cause of morbidity and mortality in patients with lower-risk

Bone Marrow Disease(s): 

AAMDSIF Joins Coalition Urging the Administration to Preserve our Nation’s Newborn Screening Program

A coalition of 272 organizations signed a public letter to the Secretary, Department of Health and Human Services, addressing the decision to eliminate the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC).  While each state may add on additional screenings, this Committee ensured standardized measurements and procedures, to endure early detection of newborn conditions.

AAMDSIF signed the letter, attached below, to endorse maintaining the Advisory Committee on Heritable Disorders in Newborns and Children.

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study

Author(s): 
Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, Hammond D, Bouligny IM, Swaminathan M, Issa G, Short N, Daver N, DiNardo CD, Kadia T, Jabbour E, Ravandi F, Roboz GJ, Savona M, Griffiths EA, McCloskey J, Odenike O, Oganesian A,
Primary Author: 
Bataller A
Journal Title: 
Blood Cancer Journal
Original Publication Date: 
Mar 2025

Hypomethylating agents (HMA) are indicated in the treatment of higher-risk

Bone Marrow Disease(s): 

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Author(s): 
Sekeres MA, Santini V, Díez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U
Primary Author: 
Sekeres MA
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Mar 2025
Bone Marrow Disease(s): 

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Author(s): 
Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M
Primary Author: 
Pullarkat V
Journal Title: 
Blood Cancer Journal
Original Publication Date: 
Mar 2025
Bone Marrow Disease(s): 

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Author(s): 
Gisriel SD, Aakash F, Bennett JM, Hasserjian RP, Loghavi S, DeZern AE, Santini V, Savona MR, Brunner AM, Buckstein R, Wei AH, Della Porta MG, Komrokji RS, Borate UM, Sekeres MA, Platzbecker U, Fenaux P, Roboz GJ, van de Loosdrecht A, Zeidan AM, Xu ML
Primary Author: 
Gisriel SD
Journal Title: 
Archives of Pathology & Laboratory Medicine
Original Publication Date: 
Mar 2025

Context.—: Standardized bone marrow reporting specifically for

Bone Marrow Disease(s): 

Advancing drug development in myelodysplastic syndromes

Author(s): 
Mina A, McGraw KL, Cunningham L, Kim N, Jen EY, Calvo KR, Ehrlich LA, Aplan PD, Garcia-Manero G, Foran JM, Garcia JS, Zeidan AM, DeZern AE, Komrokji R, Sekeres MA, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K
Primary Author: 
Mina A
Journal Title: 
Blood Advances
Original Publication Date: 
Mar 2025

Bone Marrow Disease(s): 

EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial

Author(s): 
Jang JH, Tomuleasa C, Oliynyk H, Lanamtieng T, Park J, Kim Y, Jung J, Russo P, Lim SM, Peffaultde Latour R
Primary Author: 
Jang JH
Journal Title: 
EJHaem
Original Publication Date: 
Mar 2025

Introduction: SB12 demonstrated equivalence to reference eculizumab (ECU) in complement inhibitor-naïve patients with

Bone Marrow Disease(s):